In the past 10years, the detection of Epidermal growth factor receptor (EGFR) mutation and the application of Epidermal growth factor receptor Tyrosine kinase inhibitors (EGFR-TKIs) have opened a new era in the treatment of advanced NSCLC. Here, EGFR is linked to non-small cell lung carcinoma.